Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL3 | Q96JM7 | 13/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 11/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | MBTD1 | Q05BQ5 | 5/20 | 0.36 |
| ▸ | TP53BP1 | Q12888 | 2/20 | 0.34 |
| ▸ | L3MBTL4 | Q8NA19 | 1/20 | 0.34 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2007966 | 0.93 | L3MBTL3 (0.39) | L3MBTL3L3MBTL1CYP2D6CYP2C19MBTD1 | |
| SCHEMBL2009840 | 0.93 | L3MBTL3 (0.39) | L3MBTL3L3MBTL1MBTD1ABCB1 | |
| SCHEMBL2006890 | 0.93 | L3MBTL3 (0.43) | L3MBTL3L3MBTL1CYP2D6CYP2C19MBTD1 | |
| SCHEMBL2011528 | 0.91 | SLC18A3 (0.41) | L3MBTL3L3MBTL1MBTD1ABCB1 | |
| SCHEMBL2011143 | 0.91 | SLC18A3 (0.41) | L3MBTL3L3MBTL1MBTD1ABCB1 | |
| SCHEMBL574979 | 0.89 | — | — | |
| SCHEMBL2004013 | 0.86 | L3MBTL3 (0.42) | L3MBTL3L3MBTL1CYP2D6CYP2C19MBTD1 | |
| SCHEMBL2003194 | 0.86 | L3MBTL3 (0.42) | L3MBTL3L3MBTL1CYP2D6CYP2C19MBTD1 | |
| SCHEMBL736256 | 0.84 | SLC18A3 (0.42) | L3MBTL3L3MBTL1ABCB1 | |
| SCHEMBL735809 | 0.84 | L3MBTL3 (0.38) | L3MBTL3L3MBTL1MBTD1ABCB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7960394-B2 | 3,8-dimethyl-2-[4-(3-piperidin-1-ylpropoxy)phenyl]-4(3H)-quinazolinone; 6-chloro-3-methyl-2-[4-(3-piperidin-1-ylpropoxy)phenyl]pyrido[3,4-d]-pyrimidin-4(3H)-one; 2-[4-(1-cyclopentyl-4-piperidinyloxy)phenyl]-3-methylpyrido[2,3-d]-pyrimidin-4(3H)-one; treats metabolic, nervous system, vascular disorders | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2011-06-14 | — | — | US | disclosed |
| US-20090227601-A1 | Bradykinin 1 Receptor Antagonists | AMGEN INC. (US) | 2009-09-10 | — | — | US | disclosed |
| US-20080275069-A1 | Quinazoline Derivative | MSD K.K. (JP) | 2008-11-06 | — | — | US | disclosed |
| EP-1963285-A1 | BRADYKININ 1 RECEPTOR ANTAGONISTS | Amgen Inc. (US) | 2008-09-03 | — | — | EP | disclosed |
| WO-2007067629-A1 | BRADYKININ 1 RECEPTOR ANTAGONISTS | AMGEN INC. (US) | 2007-06-14 | — | — | WO | disclosed |
| EP-1757594-A1 | QUINAZOLINE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-02-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080275069-A1 | Quinazoline Derivative | HRH3, HRH4, HRH2 | L3MBTL3 1939/4885L3MBTL1 2537/4885CYP2D6 1027/4885 |
| US-20090227601-A1 | Bradykinin 1 Receptor Antagonists | BDKRB1, BDKRB2, VIPR1 | L3MBTL3 3276/4885L3MBTL1 1537/4885CYP2D6 1667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.